<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38293509</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: A cross-sectional cohort study from China.</ArticleTitle><Pagination><StartPage>e24096</StartPage><MedlinePgn>e24096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e24096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e24096</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Although clinical trials and real-world data suggest that the risk of COVID-19 and its complications is not exacerbated in patients with psoriasis treated by biological agents, the evidence for this is still limited.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">We aimed to assess the outcomes of COVID-19 among Chinese patients with psoriasis treated by IL-23 inhibitor, and to compare these variables in patients receiving other therapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A cross-sectional cohort study was conducted to compare psoriasis treatment with IL-23 inhibitor to other treatment methods. All the patients received a questionnaire that contained questions about their psoriasis treatment, COVID-19 symptoms, and related risk factors. The prevalence of COVID-19 was calculated, and logistic regression analyses were performed to determine the association between treatment method and COVID-19 risk. The symptoms of COVID-19 and long COVID were described for each treatment group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Between December 2022 and February 2023, 732 patients with psoriasis were included in the final analysis. 549 patients had a SARS-CoV-2 infection during the study period. Our results showed that individuals who worked outdoors had a decreased risk of COVID-19, as did those who had other allergic disease. With regard to the effect of the treatment regimens, IL-23 inhibitor treatment was associated with a decreased risk of COVID-19 compared to almost all the other treatments except acitretin. Fever was the most common symptom, but the maximum temperature and duration of fever were comparable among the treatment groups. Patients treated with IL-23 inhibitor were more likely to be asymptomatic after recovery compared to patients treated with methotrexate, narrow-bound ultra violet B, or TNF-&#x3b1; inhibitor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">IL-23 inhibitor treatment may lower the risk of COVID-19 and long COVID. Thus, IL-23 inhibitor treatment might be beneficial and positively considered for patients with psoriasis who require systemic treatment during periods when there is a surge in COVID-19 cases.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuxiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Tenth People's Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200072, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiajing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yangfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-23 inhibitor</Keyword><Keyword MajorTopicYN="N">Psoriasis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>31</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38293509</ArticleId><ArticleId IdType="pmc">PMC10826651</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e24096</ArticleId><ArticleId IdType="pii">S2405-8440(24)00127-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ding X., Wang T., Shen Y., et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur. J. Dermatol. 2012;22(5):663&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">22910173</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths C., et al. Psoriasis. Lancet (London, England) 2021;397(10281):1301&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">33812489</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong A.W., Read C. Pathophysiology, clinical Presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">32427307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutlu &#xd6;., Metin A. Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol. Ther. 2020;33(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261987</ArticleId><ArticleId IdType="pubmed">32367558</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldust M., et al. Skin cancer and COVID-19. Dermatol. Ther. 2020;33(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404420</ArticleId><ArticleId IdType="pubmed">32700820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X., Chen X., Shen M. Association of psoriasis with risk of COVID-19: a 2-sample Mendelian randomization study. J. Am. Acad. Dermatol. 2022;87(3):715&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815194</ArticleId><ArticleId IdType="pubmed">35131400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwee K.V., et al. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID) J. Dermatol. Treat. 2023;34(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">36545844</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., et al. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: a systematic review and meta-analysis. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648142</ArticleId><ArticleId IdType="pubmed">36389759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.J., et al. The risk of COVID-19 in patients with psoriasis: a retrospective cohort study. J. Am. Acad. Dermatol. 2022;87(6):1395&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484859</ArticleId><ArticleId IdType="pubmed">36305697</ArticleId></ArticleIdList></Reference><Reference><Citation>Thatiparthi A., et al. Biologic treatment Algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am. J. Clin. Dermatol. 2021;22(4):425&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8051287</ArticleId><ArticleId IdType="pubmed">33861409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kridin K., et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol. Ther. 2021;34(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209905</ArticleId><ArticleId IdType="pubmed">34033207</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouqui P., et al. COVID-19 re-infection. Eur. J. Clin. Invest. 2021;51(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250303</ArticleId><ArticleId IdType="pubmed">33675046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X., et al. Reinfection in patients with COVID-19: a systematic review. Glob Health Res Policy. 2022;7(1):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9051013</ArticleId><ArticleId IdType="pubmed">35488305</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotoodeh Ghorbani S., et al. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: a systematic review and meta-analysis. J. Med. Virol. 2022;94(1):44&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427032</ArticleId><ArticleId IdType="pubmed">34411311</ArticleId></ArticleIdList></Reference><Reference><Citation>Dao T.L., Hoang V.T., Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(1):13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592450</ArticleId><ArticleId IdType="pubmed">33113040</ArticleId></ArticleIdList></Reference><Reference><Citation>De Filippo M., et al. Allergy and COVID-19. Acta Biomed. 2021;92(S7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9431895</ArticleId><ArticleId IdType="pubmed">34842592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., et al. Impact of allergic rhinitis and asthma on COVID-19 infection, hospitalization, and mortality. J. Allergy Clin. Immunol. Pract. 2022;10(1):124&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556867</ArticleId><ArticleId IdType="pubmed">34728408</ArticleId></ArticleIdList></Reference><Reference><Citation>Adir Y., et al. Asthma and COVID-19: an update. Eur. Respir. Rev. 2021;30(162)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674937</ArticleId><ArticleId IdType="pubmed">34911694</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., et al. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J. Allergy Clin. Immunol. Pract. 2021;9(2):693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725230</ArticleId><ArticleId IdType="pubmed">33309934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.M., et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J. Allergy Clin. Immunol. 2020;146(4):790&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428784</ArticleId><ArticleId IdType="pubmed">32810517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagni F., et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724&#x2013;e736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397302</ArticleId><ArticleId IdType="pubmed">34485930</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z., et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw. Open. 2021;4(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8524310</ArticleId><ArticleId IdType="pubmed">34661663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahil S.K., et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J. Allergy Clin. Immunol. 2021;147(1):60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566694</ArticleId><ArticleId IdType="pubmed">33075408</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenna B., et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490&#x2013;e506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179144</ArticleId><ArticleId IdType="pubmed">35698725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.J., Truong A.K. COVID-19 infection on IL-23 inhibition. Dermatol. Ther. 2020;33(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361849</ArticleId><ArticleId IdType="pubmed">32584451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>